Which ARV has been recommended by WHO as the most effective –
First, I need to recall the core concept. Antiretroviral therapy (ART) combinations are the standard for HIV. WHO guidelines often recommend specific regimens based on efficacy and safety. The core concept here is about which ARV regimen is most effective, so I should focus on the most recent WHO recommendations.
Now, the correct answer. WHO currently recommends a combination of drugs. The most effective might be a specific regimen like Dolutegravir-based therapy. Dolutegravir is an integrase inhibitor and is part of the first-line treatment because of its high efficacy and lower resistance rates. So if the correct answer is Dolutegravir, then I need to explain why.
Why is Dolutegravir the right choice? It's part of the preferred regimen because it has a high barrier to resistance, is once-daily, and has fewer side effects compared to older drugs like efavirenz. It works by inhibiting the integrase enzyme, preventing the virus from integrating into the host DNA.
As for the wrong options, if the other choices include older drugs like zidovudine, lamivudine, or efavirenz, I need to explain why they're not the most effective. Zidovudine is an NRTI but has more side effects. Lamivudine is often part of regimens but isn't the most effective on its own. Efavirenz, while an NNRTI, has more side effects and lower resistance barriers than integrase inhibitors.
The clinical pearl would be to remember that WHO favors integrase inhibitors like Dolutegravir in first-line ART due to their efficacy and safety profile. Students should note the shift from NNRTIs to INSTIs in recent guidelines.
Putting it all together, the correct answer is likely Dolutegravir, and the explanation should highlight its mechanism, advantages over other drugs, and WHO's current stance. Make sure each section is concise and fits within the character limit.
**Core Concept**
The World Health Organization (WHO) recommends specific antiretroviral therapy (ART) regimens based on efficacy, safety, and resistance profiles. Integrase strand transfer inhibitors (INSTIs) like **Dolutegravir** are now first-line agents due to superior virologic suppression and lower central nervous system (CNS) side effects compared to older agents.
**Why the Correct Answer is Right**
Dolutegravir is a potent INSTI that inhibits HIV integration into host DNA, blocking viral replication. It is part of the preferred WHO regimen **Dolutegravir + 3TC** (lamivudine) or **Dolutegravir + TDF** (tenofovir disoproxil fumarate) + 3TC. This regimen is favored for its high genetic barrier to resistance, once-daily dosing, and minimal metabolic toxicity. Clinical trials (e.g., Dolutegravir vs. Efavirenz) showed 93% virologic suppression at